

REMARKS/ARGUMENTS

Claims 1-47 have been subjected to restriction as pertaining to distinct inventions.

The claims have been restricted to one of the following groups:

I. Claims 1-23, and 36-44, in part, drawn to compounds of formula (I) –(Ie) and pharmaceutical compositions wherein R_1 , R_2 , R_3 , R_4 , and X are as defined in claim 1 except (1) R_1 or R_2 does not represent heterocyclyl or hetero aryl; (2) R_3 or R_4 are as defined in claim 1, wherein heterocyclyl and heteroaryl of R_3 or R_4 independently represents thienyl or imidazolynyl, or R_3 or R_4 independently represents triazole; classified in classes 514/548 various subclasses.

II. Claims 1-23, and 36-44, in part, drawn to compounds of formula (I) –(Ie) and pharmaceutical compositions wherein R_1 , R_2 , R_3 , R_4 , and X are as defined in claim 1 except (1) R_1 or R_2 does not represent heterocyclyl or hetero aryl; (2) R_3 or R_4 are as defined in claim 1, wherein heterocyclyl and heteroaryl of R_3 or R_4 independently represents isoxazole, thiazole, thiadiazole, or isothiazole; classified in classes 514/548 various subclasses.

III. Claims 1-23, and 36-44, in part, drawn to compounds of formula (I) –(Ie) and pharmaceutical compositions wherein R_1 , R_2 , R_3 , R_4 , and X are as defined in claim 1 except (1) R_1 or R_2 does not represent heterocyclyl or hetero aryl; (2) R_3 or R_4 are as defined in claim 1, wherein heterocyclyl and heteroaryl of R_3 or R_4 independently represents pyridine; classified in classes 514/548 various subclasses.

IV. Claims 1-23, and 36-44, in part, drawn to compounds of formula (I) –(Ie) and pharmaceutical compositions wherein R_1 , R_2 , R_3 , R_4 , and X are as defined in claim 1 except (1) R_1 or R_2 does not represent heterocyclyl or hetero aryl; (2) R_3 or R_4 are as defined in claim

1, wherein heterocyclyl and heteroaryl of R₃ or R₄ independently represents piperidine;
classified in classes 514/548 various subclasses.

V. Claims 1-23, and 36-44, in part, drawn to compounds of formula (I) –(Ie) and pharmaceutical compositions wherein R₁, R₂, R₃, R₄, and X are as defined in claim 1 except (1) R₁ or R₂ does not represent heterocyclyl or hetero aryl; (2) R₃ or R₄ are as defined in claim 1, wherein heterocyclyl and heteroaryl of R₃ or R₄ independently represents piperazine;
classified in classes 514/548 various subclasses.

VI. Claim 24 drawn to a process of making pharmaceutical compositions of the compound of formula (I), classified in 514, numerous subclasses.

VII. Claims 25-35, and 45-47, drawn to various methods of use (inhibiting cyclin dependent kinase, treating cancer, angiogenesis, etc) classified in classes 514, numerous subclasses.

In addition there is a requirement for an election of species which varies with the group elected for prosecution. Applicants elect Group I, claims 1-23, and 36-44, in part, as described above for further prosecution in this application. With respect to species election, Applicant elects compounds of Formula (Id), and more particularly compounds wherein X is C(S), R₂ is hydrogen, R₃ is substituted phenyl or aminophenyl, and R₄ is a thiazole. For example, see compound 128 on page 36 of the instant specification.


Applicants reserve the right to prosecute claims directed to the non-elected inventions, deemed herein as distinct, in one or more continuing or divisional applications.

DOCKET NO.: ORT-1554
Application No.: 10/029,750
Office Action Dated: January 20, 2004

PATENT

Respectfully submitted,

Date: 2/20/2004


Myra H. McCormack
Registration No. 36,602

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-6932